Honz Pharmaceutical Co., Ltd. Class A

Honz Pharmaceutical Co., Ltd. Class A

SSZSE:300086
4.53
CNY
-0.14
(-3.00%)
-0.47EPS
2.44BMarket Cap

Total Valuation

CNY

As of September 30, 2026, Honz Pharmaceutical Co., Ltd. Class A carries a market capitalization of 2.44B, placing it among publicly traded companies globally. Its enterprise value stands at 2.91B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap2.44B
Enterprise Value2.91B

Share Statistics

As of September 30, 2026, Honz Pharmaceutical Co., Ltd. Class A has 455.12M shares outstanding.

Shares Outstanding455.12M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 7.28, and the price-to-book ratio stands at 2.97.

PS Ratio7.28
PB Ratio2.97
P/TBV Ratio3.37

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 8.66 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 2.91B versus a market cap of 2.44B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales8.66

Financial Position

As of September 30, 2026, Honz Pharmaceutical Co., Ltd. Class A maintains a current ratio of 0.39, meaning it holds 0.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 53.00, indicating elevated leverage, while an interest coverage ratio of -12.02 demonstrates limited ability to service its debt obligations.

Current Ratio0.39
Quick Ratio0.01
Debt / Equity53.00
Debt / EBITDA-2.05
Interest Coverage-12.02

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Honz Pharmaceutical Co., Ltd. Class A posted a negative return on equity (ROE) of -22.35, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -11.80, reflecting losses generated across the asset base. The company generates approximately 621,462.86 in revenue per employee across its workforce of 540.00, a quick read on workforce productivity versus industry peers.

Return on Equity (ROE)-22.35
Return on Assets (ROA)-11.80
Revenue Per Employee621,462.86
Employee Count540.00

Taxes

CNY

Over the twelve months ended September 30, 2026, Honz Pharmaceutical Co., Ltd. Class A recorded an income tax benefit of -7.18M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -220.03M and -209.32M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax-7.18M

Stock Price Statistics

CNY

As of the close on November 17, 2026, Honz Pharmaceutical Co., Ltd. Class A's stock has declined approximately 59.23% over the past 52 weeks. The 50-day moving average sits at 5.45, while the 200-day moving average is 7.04.

52-Week Price Change-59.23%
50-Day Moving Average5.45
200-Day Moving Average7.04

Income Statement

CNY

Over the twelve months ended September 30, 2026, Honz Pharmaceutical Co., Ltd. Class A generated 335.59M in revenue and converted that into -209.32M in net income, yielding earnings per share of -0.47. EBITDA reached -217.98M, while operating income came in at -108.53M.

Revenue335.59M
Gross Profit180.36M
Operating Income-108.53M
Pretax Income-220.03M
Net Income-209.32M
EBITDA-217.98M
EBIT-217.98M
Earnings Per Share (EPS)-0.47

Balance Sheet

CNY

As of September 30, 2026, Honz Pharmaceutical Co., Ltd. Class A holds 5.77M in cash and equivalents against 447.49M in total debt, resulting in a net debt position of 343.25M. Total book value stands at 823.88M, with working capital of -346.57M providing operational flexibility.

Cash & Cash Equivalents5.77M
Total Debt447.49M
Net Debt343.25M
Equity (Book Value)823.88M
Book Value Per Share1.81
Working Capital-346.57M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-15.00M

Margins

Over the twelve months ended September 30, 2026, Honz Pharmaceutical Co., Ltd. Class A posted a gross margin of 53.74, reflecting its pricing power and cost economics. The operating margin of -32.34 and net profit margin of -62.37 provide insight into operational efficiency.

Gross Margin53.74
Operating Margin-32.34
Pretax Margin-65.56
Profit Margin-62.37
EBITDA Margin-64.96

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Honz Pharmaceutical Co., Ltd. Class A paid dividends of 0.03 per share. The dividend payout ratio of -6.44 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 0.79, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Honz Pharmaceutical Co., Ltd. Class A shareholders.

Dividend Per Share0.03
Payout Ratio-6.44
Shareholder Yield0.79

Stock Splits

Honz Pharmaceutical Co., Ltd. Class A's most recent stock split took place on September 30, 2015 with a 2:3 split ratio.

Last Split Date9/30/2015
Split Ratio2:3

Scores

As of September 30, 2026, Honz Pharmaceutical Co., Ltd. Class A has an Altman Z-Score of 0.97, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score0.97